<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05791552</url>
  </required_header>
  <id_info>
    <org_study_id>MUC-00</org_study_id>
    <nct_id>NCT05791552</nct_id>
  </id_info>
  <brief_title>Feasibility of a Method for Analysis of Alzheimer´s Disease Specific Proteins in Nasal Secretion</brief_title>
  <acronym>NL02</acronym>
  <official_title>Feasibility of a Method for Analysis of Alzheimer´s Disease Specific Proteins in Nasal Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noselab GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Noselab GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a first in man study investigating the feasibility of the collection, storage,&#xD;
      processing and analysis of 4 key biomarkers for the diagnosis of Alzheimer's disease [AD] in&#xD;
      nasal secretion. Nasal secretion [NS] constitutes a minimally invasive access to&#xD;
      cerebrospinal fluid [CSF]. Therefore, it could be highly suitable for detection and&#xD;
      monitoring of the AD relevant biomarkers pTau181, total Tau, Amyloid-ß1-40 and Amyloid-ß1-42.&#xD;
      This study evaluates correlations of biomarker patterns in NS and CSF. Furthermore, the&#xD;
      correlations of the 4 AD specific biomarkers in nasal secretion and CSF is investigated. For&#xD;
      this study, patients with cognitive impairment (AD and NonAD group) and healthy controls were&#xD;
      included.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2022</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of brain specific biomarkers in nasal secretion</measure>
    <time_frame>1-2 years</time_frame>
    <description>The aim of the study was to investigate the overall applicability of a new, minimally invasive, and proprietary procedure developed by the company Noselab GmbH for exclusion or detection of Alzheimer's disease (AD) and/or neurodegeneration (ND) in patients with (subjective) cognitive impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distinction of pathologic and physiologic biomarker patterns in nasal secretion</measure>
    <time_frame>1-2 years</time_frame>
    <description>Assess ranges of biomarkers for AD in nasal secretion of cognitively impaired patients with and without AD and healthy controls</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Nasal Secretion</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Brain Nose Interface</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient WITH cognitive impairment and no nasal pathologies. CSF analysis is planned or results are already available</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient WITHOUT cognitive impairment and without nasal pathologies</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Collection of nasal secretion</intervention_name>
    <description>Standardized collection of nasal secretion in the vicinity of the olfactory cleft</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Group A Patient WITH cognitive impairment and no nasal pathologies. CSF analysis is&#xD;
             planned or results are already available&#xD;
&#xD;
          -  Group B Patient WITHOUT cognitive disorder and without pathologies in the nasal area&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of an obstructing nasal cavity disease&#xD;
&#xD;
          -  Patient suffers from an acute upper respiratory tract infection (putrid rhinorrhea)&#xD;
&#xD;
          -  Inability to give consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marion San Nicoló, MD</last_name>
    <phone>+49892302680</phone>
    <phone_ext>1</phone_ext>
    <email>marion.sannicolo@noselab.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mareike Haack, MD</last_name>
    <phone>+49892302680</phone>
    <phone_ext>1</phone_ext>
    <email>mareike.haack@noselab.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Noselab GmbH</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion San Nicoló, MD</last_name>
      <phone>+49892302680</phone>
      <phone_ext>1</phone_ext>
      <email>marion.sannicolo@noselab.com</email>
    </contact>
    <contact_backup>
      <last_name>Gabriele C Baur</last_name>
      <phone>+49892302680</phone>
      <phone_ext>1</phone_ext>
      <email>gabriele.baur@noselab.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marion San Nicoló, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 14, 2023</study_first_submitted>
  <study_first_submitted_qc>March 28, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>March 28, 2023</last_update_submitted>
  <last_update_submitted_qc>March 28, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

